Found: 16
Select item for more details and to access through your institution.
Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease.
- Published in:
- Diabetologia, 2007, v. 50, n. 9, p. 1930, doi. 10.1007/s00125-007-0743-8
- By:
- Publication type:
- Article
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2011, v. 13, n. 7, p. 653, doi. 10.1111/j.1463-1326.2011.01391.x
- By:
- Publication type:
- Article
The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2011, v. 13, n. 6, p. 542, doi. 10.1111/j.1463-1326.2011.01386.x
- By:
- Publication type:
- Article
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2011, v. 13, n. 3, p. 258, doi. 10.1111/j.1463-1326.2010.01350.x
- By:
- Publication type:
- Article
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2011, v. 13, n. 1, p. 65, doi. 10.1111/j.1463-1326.2010.01326.x
- By:
- Publication type:
- Article
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
- Published in:
- Diabetes, Obesity & Metabolism, 2009, v. 11, n. 8, p. 786, doi. 10.1111/j.1463-1326.2009.01046.x
- By:
- Publication type:
- Article
The Boehringer Ingelheim employee study (Part 2): 10-year cardiovascular diseases risk estimation.
- Published in:
- Occupational Medicine, 2016, v. 66, n. 7, p. 543, doi. 10.1093/occmed/kqw084
- By:
- Publication type:
- Article
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
- Published in:
- Diabetic Medicine, 2011, v. 28, n. 11, p. 1352, doi. 10.1111/j.1464-5491.2011.03387.x
- By:
- Publication type:
- Article
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes T. Forst et al. Linagliptin added to metformin in Type 2 diabetes.
- Published in:
- Diabetic Medicine, 2010, v. 27, n. 12, p. 1409, doi. 10.1111/j.1464-5491.2010.03131.x
- By:
- Publication type:
- Article
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 3, p. 276, doi. 10.1111/dom.12419
- By:
- Publication type:
- Article
The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 10, p. 1036, doi. 10.1111/dom.12312
- By:
- Publication type:
- Article
Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2013, v. 15, n. 4, p. 364, doi. 10.1111/dom.12039
- By:
- Publication type:
- Article
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 4, p. 348, doi. 10.1111/j.1463-1326.2011.01545.x
- By:
- Publication type:
- Article
Recurrent deep venous thrombosis caused by congenital interruption of the inferior vena cava and heterozygous factor V Leiden mutation.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers.
- Published in:
- Journal of Clinical Pharmacology, 2008, v. 48, n. 10, p. 1171, doi. 10.1177/0091270008323753
- By:
- Publication type:
- Article
Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes.
- Published in:
- Clinical Endocrinology, 2009, v. 71, n. 1, p. 27, doi. 10.1111/j.1365-2265.2008.03412.x
- By:
- Publication type:
- Article